A key finding of our study is that both genetic and pharmacological STING targeting reduces CHX‐induced peritoneal fibrosis by downregulating fibrotic mediators, such as TGF‐β1, and restoring mesothelial marker expression, thereby preventing MMT. The gene discussed is STING1; the disease is Peritoneal Fibrosis.